What are the indications, recommended dosing, contraindications, and monitoring guidelines for olanzapine in adults?

Olanzapine: Indications, Dosing, Contraindications, and Monitoring

Indications

Olanzapine is FDA-approved for schizophrenia, acute manic or mixed episodes of bipolar I disorder (as monotherapy or adjunct to lithium/valproate), maintenance treatment of bipolar I disorder, and acute agitation associated with schizophrenia or bipolar I mania (intramuscular formulation). 1 When combined with fluoxetine, it is indicated for depressive episodes associated with bipolar I disorder and treatment-resistant depression. 1

• In adults with schizophrenia, efficacy was established in two 6-week trials and one maintenance trial 1
• In adolescents (ages 13-17) with schizophrenia, efficacy was demonstrated in one 6-week trial, though the increased potential for weight gain and dyslipidemia compared to adults may lead clinicians to consider other drugs first 1
• For bipolar I disorder, efficacy was established in two 3-4 week trials and one maintenance trial in adults, and one 3-week trial in adolescents 1
• Intramuscular olanzapine is indicated for acute agitation, with efficacy demonstrated in three 1-day trials 1

Recommended Dosing

Adults with Schizophrenia

Start at 5-10 mg orally once daily, with a target dose of 10 mg/day achieved within several days. 1

• Doses above 10 mg/day were not demonstrated to be more efficacious than 10 mg/day 1
• An increase above 10 mg/day (to 15 mg/day or greater) is recommended only after clinical assessment 1
• The maximum dose is 20 mg/day 1
• Meta-regression analysis suggests the likelihood of favorable response is maximized at 10-15 mg/day, with minimal additional benefit at higher doses 2

Adolescents with Schizophrenia

Start at 2.5-5 mg once daily, with a target dose of 10 mg/day. 1

• When dosage adjustments are necessary, increments/decrements of 2.5 or 5 mg are recommended 1
• The mean modal dose in clinical trials was 12.5 mg/day (mean dose 11.1 mg/day) 1
• Safety and effectiveness of doses above 20 mg/day have not been evaluated 1

Adults with Bipolar I Disorder (Manic or Mixed Episodes)

For monotherapy, start at 10 or 15 mg once daily. 1

• Short-term (3-4 weeks) antimanic efficacy was demonstrated in a dose range of 5-20 mg/day 1
• For adjunctive treatment with lithium or valproate, start at 10 mg once daily 1
• Dosage adjustments should occur at intervals of not less than 24 hours, with increments/decrements of 5 mg recommended 1

Adolescents with Bipolar I Disorder

Start at 2.5-5 mg once daily, with a target dose of 10 mg/day. 1

• The mean modal dose in clinical trials was 10.7 mg/day (mean dose 8.9 mg/day) 1
• Increments/decrements of 2.5 or 5 mg are recommended when adjustments are necessary 1

Acute Agitation (Intramuscular)

Administer 10 mg IM for acute agitation associated with schizophrenia or bipolar I mania, with lower doses of 5 or 7.5 mg when clinically warranted. 3, 1

• Clinical trials demonstrated efficacy with IM doses ranging from 2.5-10 mg 3
• Assess for orthostatic hypotension prior to subsequent dosing, with a maximum of 3 doses administered 2-4 hours apart 1
• At 2 hours after first injection, olanzapine-treated patients showed significantly greater reduction in agitation scores compared to lorazepam 3

Special Populations

In debilitated patients, those with predisposition to hypotensive reactions, hepatic impairment, or pharmacodynamically sensitive patients (e.g., nonsmoking females ≥65 years), start at 2.5-5 mg once daily. 3, 4, 1

• For elderly patients with bipolar disorder, the recommended initial dose is 2.5-5 mg orally once daily, usually at night 4
• The maximum recommended dose in elderly patients is 10 mg/day, with most responding adequately to 5-10 mg/day 3
• Avoid doses above 10 mg/day in elderly patients, as the risk-benefit ratio becomes unfavorable 3
• In patients with Alzheimer's disease, a lower starting dose of 2.5 mg is recommended 3

Dose Titration Timing

Dose adjustments should occur at intervals of not less than 1 week after initial titration, as steady-state concentrations require approximately one week to achieve. 3

• Dose titration should not increase more frequently than every 1-2 weeks after initial titration to avoid unnecessary side effects before steady-state is achieved 3

Administration Timing

Administer olanzapine at bedtime when used for insomnia or sleep disturbances. 3

• Choose bedtime dosing if the patient is using olanzapine for insomnia or sleep disturbances 3
• Consider morning dosing only if the patient experiences paradoxical activation or if bedtime dosing causes next-day hangover effect that impairs function 3
• Olanzapine may be given without regard to meals 1

Contraindications

There are no contraindications with olanzapine monotherapy. 1

• When using olanzapine in combination with fluoxetine, refer to the contraindications section of the Symbyax package insert 1
• When using olanzapine in combination with lithium or valproate, refer to the contraindications sections of those product inserts 1

Critical Warnings and Precautions

Black Box Warning: Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death; olanzapine is not approved for treatment of patients with dementia-related psychosis. 4, 1

• The FDA black box warning regarding increased mortality should be considered when prescribing olanzapine to elderly patients with cognitive impairment 3
• There is also an increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack) in this population 1

Metabolic Changes

Atypical antipsychotics, including olanzapine, are associated with hyperglycemia, dyslipidemia, and weight gain. 1

• Approximately 40% of patients experience weight gain with olanzapine 3
• Weight gain, diabetes, and dyslipidemia are the most important long-term risks requiring systematic monitoring 3
• Metabolic effects should be monitored with long-term use 3

Drug Interactions and Combination Risks

Fatalities have been reported with concurrent use of benzodiazepines and high-dose olanzapine due to oversedation and respiratory depression. 3, 4

• Use caution when combining with benzodiazepines, and use the lowest effective doses of both agents 3
• Exercise caution when combining olanzapine with metoclopramide, phenothiazines, or haloperidol to avoid excessive dopamine blockade 3, 4
• Avoid combining olanzapine with other antipsychotics such as aripiprazole due to increased risk of extrapyramidal symptoms 3

Other Serious Risks

• Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring 1
• Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Discontinue if DRESS is suspected 1
• Suicide risk: The possibility of suicide attempt is inherent in schizophrenia and bipolar I disorder; close supervision of high-risk patients should accompany drug therapy 1
• Tardive Dyskinesia: Monitor for extrapyramidal symptoms, though olanzapine has diminished risk compared to typical antipsychotics 3, 1

Monitoring Guidelines

Baseline Monitoring

Prior to initiating olanzapine, obtain baseline metabolic parameters and blood pressure (including orthostatic vital signs). 3

• Monitor blood pressure at baseline and during dose titration, focusing on orthostatic hypotension 3
• Consider ECG monitoring only if patient has known cardiac arrhythmias, structural heart disease, or concurrent use of other QTc-prolonging medications 3
• Olanzapine is associated with lower risk of QT interval prolongation compared to typical antipsychotics and does not require baseline ECG monitoring 3

Ongoing Monitoring

Monitor metabolic parameters (weight, glucose, lipids) aggressively throughout treatment, as these are the most important long-term risks. 3

• Weight gain should be monitored aggressively, with consideration of concurrent metformin for metabolic protection 3
• Monitor for common side effects including drowsiness, sedation, and fatigue 3, 4, 5
• In elderly patients, monitor daily for excessive sedation, falls, and orthostatic hypotension 3
• Monitor for extrapyramidal symptoms, which can occur at therapeutic doses though less commonly than with typical antipsychotics 3

Therapeutic Drug Monitoring

The optimal therapeutic range of olanzapine serum levels is 20-40 ng/mL. 6

• Therapeutic drug monitoring may be useful in patients suspected of nonadherence, where there is potential for drug interaction, and in patients taking 15 mg/day or more who have not reached clinical response 2
• Higher doses may be considered if 15 mg is ineffective and plasma level is less than 20 ng/mL on that dose 2
• Concentrations of 80 ng/mL are considered threshold for occurrence of adverse events 6
• There is a direct linear relationship between olanzapine dose and plasma concentration 2

Duration of Treatment Assessment

Evaluate therapeutic response and maintain the therapeutic dose for at least 4 weeks before considering the medication ineffective for positive symptoms. 3

• After 9 months, dosage reduction should be used to reassess the need to continue medication 3
• The healthcare provider who elects to use olanzapine for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient 1

Pharmacokinetic Considerations

Smoking and carbamazepine induce cytochrome P450 isoenzymes and decrease olanzapine serum levels, while fluvoxamine inhibits CYP1A2 and increases concentrations. 6

• Oxidative processes are mediated primarily by CYP1A2 and to a minor degree by CYP2D6 6
• Clinically relevant CYP2D6 inhibition was observed only in combination with additional factors such as female gender or old age 6
• Moderate renal or hepatic impairment calls for control of serum levels to provide maximal safety 6